NBTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Nanobiotix SA is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has strong analyst support and promising clinical catalysts, but the current technical setup is weak, hedge funds are aggressively selling, there is no fresh news catalyst in the last week, and there is no Intellectia buy signal today. Given the user wants a direct answer and is unwilling to wait for an ideal entry, the better call is to hold rather than buy at this pre-market level of 35.33.
NBTX is in a mixed-to-bearish short-term technical position. The MACD histogram is -1.005, which is below zero and still negative, showing downside momentum remains in place even though it is contracting. RSI_6 at 40.208 is neutral but leaning weak, not yet signaling strong accumulation. Moving averages are converging, which usually suggests a possible inflection point, but there is no confirmed breakout. The stock is trading below the pivot level of 36.201, with immediate resistance at 39.662 and support at 32.74. Pre-market price of 35.33 sits below pivot and closer to support than resistance. Based on the pattern data, similar candlestick setups point to a 70% chance of negative follow-through over the next day, week, and month, which weakens the case for an immediate buy.
Analysts remain broadly constructive. H.C. Wainwright raised its target to EUR 60 and kept a Buy rating after updated efficacy results from the Phase 2 CONVERGE study of JNJ-1900 in stage 3 inoperable NSCLC. UBS also lifted its target sharply to $30 from $3.50, reflecting improved biotech sentiment, de-risking from Johnson & Johnson involvement, and non-dilutive royalty financing. Other firms including Guggenheim and Leerink also raised targets and maintained positive ratings. The key long-term catalyst remains continued clinical progress in JNJ-1900 and the broader platform story around Curadigm Nanoprimer technology.
There has been no news in the last week, so there is no fresh event-driven momentum right now. Hedge funds are selling aggressively, with selling up 1048.78% over the last quarter, which is a major negative sentiment signal. Insiders are neutral, so there is no insider accumulation to offset the institutional selling. UBS noted the stock may already be fairly valued and that the next major Phase 3 NANORAY-312 data is not expected until 1H27, limiting near-term upside. The technical pattern data also points to short-term downside pressure.
No usable financial snapshot was provided, so latest quarter revenue, earnings, and growth trends cannot be assessed from the supplied data. The most recent clearly referenced company update is Q4 results on 2026-04-01, which analysts described as in line with expectations, but no detailed financial figures were included.
Analyst sentiment is mostly positive but more mixed on valuation. H.C. Wainwright, Guggenheim, and Leerink all raised price targets and kept Buy/Outperform-type ratings, showing confidence in the clinical pipeline. However, UBS upgraded its target sharply but kept only a Neutral rating, suggesting the stock may have already priced in much of the near-term good news. Overall, Wall Street pros see credible upside potential from trial progress, but the near-term upside looks limited and more dependent on longer-dated clinical execution.
